Interventional structural cardiologists at Tampa General Hospital and USF Health have completed the first TricValve System procedure in Florida under the FDA Early Feasibility Study. The novel treatment is in development to address critical cardiac patients with a life-threatening condition and represents a significant milestone for the academic medical system’s minimally invasive valve program.
The TricValve procedure was on a Central Florida patient with severe Tricuspid Regurgitation (TR), a life-threatening cardiac condition.
Dr. Hiram Bezerra, director of the TGH Minimally Invasive Valve program, director of the TGH Interventional Cardiology Center of Excellence and a professor at the USF Health Morsani College of Medicine, and Dr. Fadi Matar, Interventional Heart Failure program director, Cardiac Cath Lab medical director at the TGH Heart & Vascular Institute and professor and chief of cardiology at the USF Health Morsani College of Medicine, conducted the procedure. This is part of the TRICAV 1 clinical study led by the Internal Medicine clinical research team at the University of South Florida to evaluate the use of the medical device for potential broader use on patients.
“Cardiac disease remains the leading cause of death in America, with severe tricuspid regurgitation representing a significant, unmet medical need,” Dr. Bezerra explained. “Tampa General is committed to constant innovation and assessment of therapeutic options that may provide a benefit over current standard of care treatments for our patients…